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Identifyingwhichspeciﬁcneuronalphenotypesarevulnerabletoneonatalhypoxia-ischemia,whereinthebraintheyaredamaged,
and the mechanisms that produce neuronal losses are critical to determine the anatomical substrates responsible for neurological
impairments in hypoxic-ischemic brain-injured neonates. Here we describe our current work investigating how the serotonergic
network in the brain is disrupted in a rodent model of preterm hypoxia-ischemia. One week after postnatal day 3 hypoxia-
ischemia, losses of serotonergic raph´ e neurons, reductions in serotonin levels in the brain, and reduced serotonin transporter
expression are evident. These changes can be prevented using two anti-inﬂammatory interventions; the postinsult administration
of minocycline or ibuprofen. However, each drug has its own limitations and beneﬁts for use in neonates to stem damage to the
serotonergic network after hypoxia-ischemia. By understanding the fundamental mechanisms underpinning hypoxia-ischemia-
induced serotonergic damage we will hopefully move closer to developing a successful clinical intervention to treat neonatal brain
injury.
1.GeneralCharacteristicsof
Neonatal BrainInjury
Approximately 4 in 1000 babies are born each year with
brain damage. Being born premature (<37 weeks gestation)
and exposure to a hypoxic-ischemic insult (HI; reduced
oxygen and blood ﬂow to the brain) are the major risk
factors that contribute to this statistic [1, 2]. An HI insult
can ensue after many possible factors including placen-
tal dysfunction, haemorrhage, hypotension, umbilical cord
occlusion, and stroke [1]. A considerable number of these
preterm neonates estimate as high as 50% [3], develop
neurological and functional impairments such as cerebral
palsy, motor deﬁcits, sleep disorders, hyperactivity, anxiety,
depression, and cognitive and autonomic disabilities [4–8].
These lifelong disabilities place enormous burdens on the
individual as well as family, healthcare, educational, and
community resources.
Although signiﬁcant advances in neonatal care have
increased survival rates of preterm infants, particularly those
less than 28 weeks gestation, a concomitant decrease in
morbidity has not been achieved. In addition, aside from the
recent development of early cooling of the neonatal brain
[9, 10], there is no therapeutic intervention available to treat
neonatal brain injury. Thus the substantial associated life-
long burdens are growing and there is an urgent need to
identify neuroprotective drugs that target neuronal networks
to prevent, slow, or abate the deleterious eﬀects of HI in the
neonatal brain.
Whitematterdamageisahallmarkfeatureofbraininjury
after HI in the preterm neonate. Enlarged ventricles (ven-
triculomegaly), loss of vulnerable oligodendrocyte progen-
itor cells, periventricular leukomalacia (PVL), hypomyeli-
nation, thinning of the corpus callosum, astrogliosis, and
microgliosis are typical features of white matter damage
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for the mechanisms contributing to this injury have been
major avenues of investigation in the area of preterm
HI brain injury. However, neuronal loss is also a critical
neuropathological feature of HI and the pattern of brain
injury in preterm neonates is described as a combination
of white and grey matter damage [11–13]. Moreover, it is
plausible that disrupted neuronal function and neural circuit
connectivity are a consequence of white matter loss and
axonal disruption.
2. NeuronalDamage inthe PretermHIBrain
With the advent of more sophisticated and higher resolution
imaging techniques scientists are beginning to discriminate
white and gray matter, delineate neural connectivity, and
identify biochemical markers so that brain injury in the
neonate is increasingly being characterized in much ﬁner
detail. It is well established that there are volumetric reduc-
tions in certain brain areas of HI-aﬀected preterm infants
including the thalamus, basal ganglia, and cerebral cortex
and that these eﬀects are manifested in association with PVL
and other white matter features [17–21]. Axonal pathology
and neuronal injury have been reported in these regions as
wellasinthebrainstem,cerebellum,striatum,hippocampus,
and hypothalamus after HI in the human preterm brain [8,
22–24] and animal models [25–28]. Furthermore, long-term
changes in neuronal neurotransmitter content and release
can also occur after neonatal HI [29–32]. Disruption of
neuropeptides and neurotransmitters, critical for the devel-
opment of synapses and formation of neuronal networks,
has been postulated to underlie behavioural deﬁcits and
neuroendocrine disorders in the growing child and adult
human with a history of preterm HI [33]. It is pertinent that
some types of neurons (e.g., dopaminergic, noradrenergic,
and cholinergic neurons) may be more vulnerable to peri-
natal injury than others (e.g., magnocellular neurons in the
hypothalamus) [28, 34–36].
Identifying which speciﬁc neuronal phenotypes are
vulnerable to HI, where in the brain they are damaged,
the timing and mechanisms underlying neuronal losses
are necessary directions to establish the anatomical sub-
strates underpinning functional impairments in HI-aﬀected
neonates. These are important issues to determine because if
particular neuronal phenotypes or brain regions are injured
at diﬀerent times or diﬀer in their vulnerability to HI
then selective neuroprotective interventions may also be
temporally and spatially distinct. One neural network that
we have a particular focus on is the serotonergic system in
the brain.
3. The Serotonergic System: A Candidate
NetworkDisruptedafterNeonatalHI
Virtually all brain regions reportedly injured after neonatal
HI receive substantial serotonergic ﬁbre projections from
the brainstem. In addition, the rostral brainstem, where
serotonergic cell bodies reside, is damaged after neonatal
HI [8]. It is well established that interruption of the central
serotonergic system can lead to numerous functional deﬁcits
and many outcomes are similar to those observed in preterm
neonates exposed to HI. These observations prompted us to
hypothesise the serotonergic network in the brain is a major
systemthatisdisruptedafterpretermHIandthatthissystem
is a pivotal neural candidate to target with neuroprotective
interventions after preterm HI.
Serotonin (5-hydroxytryptamine, 5-HT) is pivotal in
fetal and postnatal brain development [37]. The serotonergic
network in the brain develops very early during gestation
and is one of the ﬁrst transmitter systems to appear in the
developing brain. Indicative of its pervasive innervation of
thecentralnervoussysteminthepostnatalandmaturebrain,
5-HT is a neurochemical that is involved in a vast array of
functions. In addition, dysfunction of serotonergic neuro-
transmission has been implicated in a host of physiological,
metabolic, and behavioural changes in disease states such
as epilepsy, depression, movement disorders, autism, anxiety
and sudden infant death syndrome (SIDS) [38–43]. In the
context of neonatal brain injury, it is pertinent that many of
these deﬁcits match those observed in HI-aﬀected neonates
[4, 5, 7, 44]. In addition, decreased serotonergic function is a
hallmark feature of depression and depressed patients show
31% loss of dorsal raph´ en e u r o n s[ 45]. Cerebral palsy is a
notable disability in some HI-aﬀected neonates and these
patients have been reported to suﬀer depression [46, 47].
Although, whether altered serotonergic function accounts
for certain HI-induced neurological deﬁcits is not known. It
is important to ﬁrst characterise the eﬀects of neonatal HI
on major elements of the serotonergic system in the brain
andbegintodecipherwhetherthesespeciﬁcnucleiconstitute
primary candidate networks that underpin neonatal HI-
induced neurological deﬁcits.
Utilising a postnatal day 3 (P3) HI model of preterm
HI we have recently investigated how P3 HI aﬀects the
serotonergic system in the brain. The P3 rat pup is subjected
to HI by right common carotid artery ligation followed by
6% oxygen for 30min. In the rat, the P3 brain development
stage is analogous to the preterm human neonate brain at
approximately 24–28 weeks gestation in terms of cellular
development, number of synapses, neurochemical develop-
ment, and cortical organization [48]. This preclinical model
produces typical behavioural and pathological features
including encephalopathy and hypomyelination observed in
human preterm neonates aﬀected by HI [4, 28, 48–51].
4. The SynthesisandRelease of 5-HT in
the Central NervousSystem
Serotonin is synthesised in the brain in serotonergic neurons
from the amino acid L-tryptophan and its metabolite 5-
hydroxytryptophan (5-HTP). Synthesis occurs via trypto-
phan hydroxylase (TpH), 5-HT’s rate-limiting enzyme and
a second enzyme amino acid decarboxylase. Two isoforms
of TpH are known to exist (TpH1 and TpH2)b u to n l y
TpH2 is found in the brain [52]. The major regulator of 5-
HT levels in the brain is the serotonin transporter (SERT).
The transporter consists of 12 transmembrane domains
that span the presynaptic membrane of 5-HT-releasingNeurology Research International 3
cells [53]. Localised on the presynaptic membrane of sero-
tonergic neurons, SERT terminates serotonergic signalling
by the eﬃcient reuptake of extracellular serotonin back
into the presynaptic neuron (Figure 1) thereby controlling
the duration of action and post-synaptic signalling of 5-
HT in the brain. Consequently, SERT is a major target for
drugs such as selective serotonin reuptake inhibitors (SSRIs)
that can increase 5-HT availability in the brain and are
useful drugs in the treatment of depression. Serotonin is
also broken down by monoamine oxidase (MAO) enzymes,
preferentially MAO-A, into 5-hydroxyindoleacetic acid (5-
HIAA); serotonin’s major metabolite.
Nine groups of 5-HT-containing cell bodies represented
in raph´ e subdivisions in the pons and upper brainstem were
ﬁrst described using histochemical techniques and desig-
nated B1−9 [54]. The bilateral raph´ es u b d i v i s i o n sa r ep r e -
dominantlypopulatedwithserotonergicneuronalcellbodies
and provide an extensive serotonergic network throughout
the central nervous system. Based on their cytoarchitecture,
neurochemistry, and neural projections, nomenclature for
the clusters of 5-HT neurons describes their location in the
dorsal, lateral, midline, or caudal portion of the pons and
medulla oblongata [55, 56].
5.SerotonergicDamagein
the ImmatureBrain after HI
In human neonates with HI encephalopathy tryptophan
hydroxylase, the 5-HT rate-limiting enzyme, is reduced in
the brainstem [41, 57]. Damage to human dorsal brainstem
nuclei, where serotonergic cell bodies are located, is also
apparent [8]. However, until our initial study in 2010 in
a rodent P3 HI model [58], information about the eﬀects
of HI on speciﬁc raph´ e nuclei was scarce. We found an
overall signiﬁcant loss of 5-HT-positive raph´ en e u r o n sa f t e r
P3 HI, consistent with previous animal studies [59, 60]a n d
reports from human neonates [8]. However it is interesting
that certain serotonergic raph´ e nuclei appear to be more
vulnerable to P3 HI-induced injury than others. One week
afterP3HI,5-HT-positiveneuronallossesoccurinthedorsal
raph´ e caudal, dorsal raph´ e ventrolateral, and dorsal raph´ e
dorsalnuclei.Incontrast,thedorsalraph´ einterfascicularand
the raph´ e magnus nuclei showed no reduction in number of
5-HT-positive neurons on P10 and P45. Six weeks after P3
HI,onP45,onlythedorsalraph´ eventrolateralandthedorsal
raph´ e dorsal demonstrated a maintained and signiﬁcant
decrease in numbers of 5-HT-positive neurons [58].
The rostrocaudal distribution of the raph´ e serotonergic
neurons may determine their vulnerability to HI injury. It
is evident that the anterior raph´ e subdivisions are more
aﬀected by P3 HI than the more posterior and caudally
located raph´ e nuclei such as the raph´ em a g n u sa n dt h e
dorsal raph´ e interfascicular nuclei [58]. The topographical
clustering of diﬀerent raph´ e subdivisions in the midbrain
and brainstem also represents diﬀerential connectivity pat-
terns in the brain. As such the dorsal raph´ e caudal, dorsal
raph´ e ventrolateral, and dorsal raph´ ed o r s a ln u c l e ip r i m a r -
ily innervate the cerebral cortex, basal ganglia, thalamus,
hypothalamus, hippocampus, and amygdala [55, 61, 62].
Presynaptic neuron Postsynaptic neuron
5HT
5HT
5HT
5HT
TpH 5HTR
SERT
SERT
Tryptophan
MAO
5HIAA
5-HTP
Figure 1: Schematic diagram depicting the major pathways
involved in the synthesis, release, re-uptake and metabolism of
serotonin in serotonergic neurons. Components of the ﬁgure have
been modiﬁed from Motifolio. TpH: tryptophan hydroxylase; 5-
HTP: 5-hydroxy-L-tryptophan; 5-HT: serotonin; SERT: serotonin
transporter; MAO: monoamine oxidase; 5-HIAA: 5-hydroxyindol-
eacetic acid; 5-HTR: serotonergic receptor.
In contrast, the more caudal nuclei predominantly send
neural projections to the spinal cord and other parts of the
brainstem[63].Theaﬀerentandeﬀerentconnectionsofeach
raph´ e subdivision are integral to producing characteristic
serotonergic-dependent functions. Thus selective losses of
serotonergic raph´ e nuclei may underpin particular deﬁcits
reported in HI-aﬀected preterm infants. On the other hand,
it appears that the more caudal raph´ em a g n u sa n dd o r s a l
raph´ e interfascicular nuclei are not susceptible to P3 HI
injury and therefore the serotonergic innervation of the
spinal cord remains relatively intact and functional after P3
HI [58]. Indeed previous reports suggest that spinal cord
injury only occurs after severe neonatal HI insults [64, 65].
Functional disruption of the serotonergic system after
neonatal HI is clearly reﬂected in the reduction in 5-
HT levels in the brain. We and others have demonstrated
reduced 5-HT levels in cortical, thalamic, and brainstem
regions after HI produced in the immature rodent brain
[66, 67]. The losses of brainstem dorsal raph´ en e u r o n sa n d
their neural projections after HI are most likely responsible
for the reduced 5-HT levels in the forebrain. Although
regional diﬀerences are apparent, the association between
direct serotonergic neural inputs to forebrain regions from
speciﬁc raph´ e nuclei in the brainstem is not known. Thus
determining whether speciﬁc ascending and descending
neural connections are disrupted after HI injury may predict
raph´ enucleivulnerabilitytoP3HIinjuryandtheeﬀectsthey
have on brain regions innervated by serotonergic aﬀerents
and eﬀerents.
In concert with the loss of raph´ en e u r o n sa n dr e d u c t i o n s
in 5-HT levels in the brain, SERT expression is signiﬁcantly
reduced in the brain [58, 67, 68]. We have characterised
SERT losses after P3 HI using both Western blot and
immunolabelling techniques. The distribution of SERT in
ﬁbres, dendrites, cell bodies, and axon terminals [69]m a k e s
it an excellent marker of the serotonergic network in the
brain [70, 71]. As such the distribution of SERT in the
brain closely reﬂects that of serotonergic neuronal cell bodies4 Neurology Research International
and innervating ﬁbres [72, 73]. Serotonergic ﬁbre losses and
damage are observed after P3 HI in several key forebrain
regions such as the motor and somatosensory cortex, lateral
hypothalamus, ventrolateral thalamus, and horizontal limb
of the diagonal band [67]. The parallel and concomitant
reductions in 5-HT levels and SERT indicate that there was
reduced availability of 5-HT for release as well as limited
reuptakeof5-HT.Thisisanalogoustoﬁndingsafterischemia
in P7 rat pups whereby there is concurrent attenuation of 5-
HT and its major metabolite, 5-hydroxyindoleacetic acid (5-
HIAA), suggesting that injury to the serotonergic neuronal
network ensues rather than direct modulation of SERT itself
or of serotonergic metabolism [66]. We therefore speculate
that P3 HI induces disruption to the serotonergic system as a
result of loss or damage to serotonergic neurons.
The eﬃcient reuptake of 5-HT is primarily dependent
on the localisation of SERT on cell bodies, dendrites, and
ﬁbres of serotonergic neurons in the central nervous system
[72]. However there is evidence that the reuptake of 5-HT
can occur by glial cells whereby SERT may be also localised
on astrocytes [74–77] and/or microglial cells [78]. Thus glial
SERT could potentially assist in the clearance of 5-HT from
the serotonergic synapse [74]. However of the few studies
that have speciﬁcally examined this possibility, most have
only reported localisation of SERT in glial cell lines and
primarycultures.Throughourowninvivoinvestigations,we
have found no evidence of SERT localisation on microglia or
astrocytes in the normal or P3 HI-injured neonatal rodent
brain (unpublished).
From our studies it is interesting to note that, in general,
proportionately greater serotonergic changes occur in the
forebrain regions compared to the brainstem raph´ e nuclei
[58, 67, 68]. This observation has led us to speculate
that damage to the serotonergic ﬁbres in the forebrain
core/penumbral areas of the HI-injured brain may occur
before injury to the brainstem raph´ e nuclei. In our P3 HI
model in the rodent, ligation of the common carotid artery
aﬀects a vascular ﬁeld encompassing primarily forebrain
regions, whereas the brainstem lies outside this vascular
ﬁeld and is seemingly spared of immediate hypoxic and
ischemic conditions. It has been shown that blood ﬂow to
the brainstem tends to increase during HI [79]. In addition
we have consistently found that, unlike the forebrain, there
is no change in brainstem hemisphere area after P3 HI
[28, 58, 67, 68]. The dorsal raph´ e nuclei can be considered
remote from the damaged forebrain sites and therefore
serotonergic neuronal injury in the brainstem might develop
as a result of secondary mechanisms. One such secondary
injury mechanism that we have had a particular focus on is
P3 HI-induced neuroinﬂammation.
6. Role of Neuroinﬂammation in
ProducingNeuronal Injury
Two phases of injury can be deﬁned after a neonatal HI
insult; an early primary phase within 24–48h causing mainly
irreversible injury in the brain and a later secondary injury
phase then ensues. Early neuronal injury after HI is thought
to evolve primarily via necrosis resulting from excitotoxic
damage produced by excessive release of glutamate from
presynaptic nerve terminals and astrocytes, causing calcium
overloadandcelldeath[80].Braininjuryduringtheprimary
phase can also result from high levels of free radicals
including reactive nitrogen species and reactive oxygen
species accumulating in the brain tissue [81, 82]. Both
caspase-dependent and caspase-independent mediators of
cell death are also initiated after neonatal HI [83, 84].
The subsequent secondary phase can continue for weeks,
months, or longer after HI. A vast array of mechanisms
may contribute to neuronal injury during this phase and the
majority of these have been identiﬁed as features of neu-
roinﬂammation. Key features of this phase include increased
numbers of activated microglia, astrogliosis, increased
levels of proinﬂammatory cytokines (e.g., interleukin-1β
(IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-
6 (IL-6), decreased levels of anti-inﬂammatory cytokines,
increased cyclooxygenase (COX-1 and COX-2) expression,
prostaglandins (PGE2 and PGI2), nuclear factor kappa-light-
chain-enhancer of activated B cells, increased expression
of chemokines and chemokine receptors, cell adhesion
moleculeexpression,andmatrixmetalloproteinases[85–89].
Proinﬂammatory cytokines, particularly IL-1β and TNF-α,
are synthesized and released by activated microglia although
IL-1β is also expressed by astrocytes and developing oligo-
dendrocytes [90–92]. Astrocytes are important sources of
lactate, neurotrophic factors, and pyruvate for neurons and
contribute to maintaining neurotransmitter and metabolic
homeostasis in the brain [93, 94]. However, although
inhibition of astrogliosis after neonatal HI improves the
survival of newborn neurons it does not alter infarct volume
[95]. The inﬁltration of peripheral cells such as lymphocytes,
neutrophils, and mast cells can also ensue if there is suﬃcient
breakdown and leakage across the blood-brain barrier [89,
96, 97]. The hallmark feature of neuroinﬂammation in the
HI-aﬀe c t e db r a i nt h a tw eh a v ef o c u s e do n ,i nt e r m so fa
potential mechanism underpinning serotonergic neurode-
generation, is the elevated number of activated microglia.
Numbers of activated microglia peak within the ﬁrst
week after HI although can remain elevated for weeks or
months after the initial ischemic episode as observed in
human and preclinical studies [68, 84, 89, 91, 98–100].
Microglia are the resident immune cells of the CNS that, in
the normal brain, survey the extracellular environment and
scavenge and clear the brain of debris and dying cells [101–
103].Howevermicroglia canalsorespond quicklytochanges
induced by HI in the brain and within 48h can switch from
a resting to an active state, multiply and migrate to sites of
ischemic injury [104, 105]. Activated microglia produce and
release excessive levels of IL-1β and TNF-α [50, 84, 89, 100,
106],thataretoxictoneurons,cancauseneurodegeneration,
and negatively aﬀect the neurodevelopment of neonates
[107, 108]. We have demonstrated that numbers of activated
microglia and levels of TNF-α and IL-1β in the brain are
elevated over the critical ﬁrst week after P3 HI, particularly
in the cortex, thalamic nuclei, and white matter, and closely
parallel injury to the serotonergic system [67, 109]. Thus
an association between neuroinﬂammation and serotonergic
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is a critical window of opportunity for interventions that
target neuroinﬂammation. Two anti-inﬂammatory drugs
are proving to be potential interventions to ameliorate
HI-induced damage to the serotonergic system. These are
minocycline and ibuprofen.
(a) Eﬀects of Minocycline on the Serotonergic System after
Neonatal HI. T h er o l eo fa c t i v a t e dm i c r o g l i aa n dr a i s e d
levels of proinﬂammatory cytokines in contributing to sero-
tonergic neuronal disruption can be addressed by blocking
microglial function with anti-inﬂammatory drugs. Minocy-
cline is a broad-spectrum antibiotic that also has anti-
inﬂammatory properties in the brain primarily because it is
a potent inhibitor of activated microglia [110, 111]. Minocy-
cline does not appear to aﬀect astrocytes after neonatal HI
[84, 111, 112]. Minocycline readily crosses the blood-brain
barrier after systemic delivery [113, 114] and is an eﬀective
neuroprotective intervention when delivered after-insult [50,
67, 83, 115, 116]. The opportunity to alter HI-induced brain
injury after the insult is an important prospect because
clinical diagnosis of HI in the preterm neonate is often not
made until 3 days after birth, well into the secondary injury
phase. Furthermore it is diﬃcult to predict if an HI insult
is imminent and therefore prophylactic treatments during
pregnancy or labour are diﬃcult to administer.
Recent studies in the adult rat demonstrate that
minocycline reverses 3-nitropropionic acid neurotoxicity-
induced changes in 5-HT levels [117] and reduces the
3,4-methylenedioxymethamphetamine-induced reduction
in SERT expression [118]. We have now shown in our
neonatal model that minocycline, initiated 2h after P3 HI
and administered daily for 1 week, inhibits P3 HI-induced
microglial activation and TNF-α and IL-1β levels and also
results in fewer raph´ e neurons being lost, maintenance of
normal 5-HT levels, and increases SERT expression [67].
However not all eﬀects of minocycline on the serotonergic
system damage are completely prevented. Furthermore,
using the same 1-week-long minocycline regimen, HI-
induced neuroinﬂammation is still inhibited 6 weeks later
[68] but minocycline’s long-term neuroprotection of the
serotonergic system is less eﬀective than at P10. At 6 weeks
after-HI SERT expression and serotonergic ﬁbre content
appear to be close to control levels but 5-HT levels remain
reduced [68]. Nonetheless minocycline, a robust inhibitor of
P3 HI-induced neuroinﬂammatory mediators, signiﬁcantly
improves serotonergic outcomes; however, HI induced
damage to the serotonergic network.
Although minocycline treatment could be a novel ther-
apy to minimise serotonergic changes after neonatal HI
and preserve the integrity of 5-HT neurocircuitry in the
brain, the use of minocycline in neonates is controversial.
Minocyclineisanexcellenttooltoblockmicroglialactivation
and has considerable neuroprotective eﬀects, not only in
neonatal HI animal models. Moreover minocycline has
proven to be highly beneﬁcial in numerous adult human
trials to treat a variety of neurodegenerative conditions
[119–122]. Nevertheless its use in human neonates must
be undertaken with caution because of the adverse eﬀects
associatedwithchronictetracyclinethathistoricallyhavetar-
nished their administration to neonates [123]. Minocycline
can produce bone stunting, staining, and pitting of teeth
[123–125]. Tetracyclines may also prevent the binding of
bilirubin to albumin and possibly lead to bilirubin-induced
brain damage in neonates. In contrast, recent studies have
demonstrated that minocycline does not produce some of
the side eﬀects historically associated with tetracycline use
in neonates [126–129]. The development of new derivatives
of minocycline, with fewer adverse side eﬀects, could be
promising interventions to develop for clinical translation.
Alternatively, given the potential of anti-inﬂammatory inter-
ventions to prevent serotonergic injury, testing other anti-
inﬂammatory drugs that may be more clinically acceptable
for use in neonates is a rational approach.
(b)EﬀectsofIbuprofenontheSerotonergicSystemafterNeona-
tal HI. Nonsteroidal anti-inﬂammatory drugs (NSAIDs)
constitute an alternative anti-inﬂammatory treatment to
stem brain injury after neonatal HI. In this class, drugs
such as ibuprofen and indomethacin are commonly used
to treat patent ductus arteriosus in preterm neonates [130,
131]. Ibuprofen is a lipophilic compound and after systemic
delivery easily crosses the blood-brain barrier [132]. A
canonical mechanism of action of NSAIDs is to inhibit
cyclooxygenase 1 and 2 enzymes (COX-1, COX-2) and the
conversion and synthesis of arachidonic acid to downstream
inﬂammatoryeﬀectorssuchascytokinesandprostaglandins.
Systemic delivery of ibuprofen can inhibit central neu-
roinﬂammation and elicit neuroprotective eﬀects although
these outcomes have primarily been demonstrated in adult
models of cerebral ischemia [133–136]. In human preterm
neonates (<28 weeks gestation) indomethacin reduces white
matter loss [137] although ibuprofen combined with ascor-
bic acid treatment in neonates reportedly has little eﬀect on
brain injury after severe HI [138]. Consistent with previous
studies [86, 139–142], we have shown that COX-2 is elevated
in the brain after P3 HI and that ibuprofen signiﬁcantly
prevents this eﬀect as well as P3 HI-induced increases in
numbers of activated microglia, IL-1β,a n dT N F - α levels
[143]. In association with these anti-inﬂammatory eﬀects
ibuprofen ameliorated reductions in cerebral hemisphere
size, O4-positive pre-myelinating, O1-positive immature
oligodendrocyte cell counts, and myelin content [143].
T h ep o t e n t i a lo fi b u p r o f e nt ob ean e u r o p r o t e c t i v e
agent in neonates to stem HI brain injury is further
supported by ﬁndings that systemic indomethacin or COX-
2 inhibitors (NS398) attenuate inﬂammatory changes as
well as functional impairments after neonatal HI in the
rodent [142, 144, 145]. In contrast, the eﬀects of NSAIDs
on serotonergic neuronal injury after HI are not known.
Preliminary evidence in our preclinical HI model indicates
that ibuprofen prevents reductions in SERT expression,
5-HT levels (in the frontal cortex and thalamic nuclei),
and serotonergic raph´ e neuronal counts (unpublished). Our
ﬁndings suggest that ibuprofen is as eﬀective at preventing
serotonergic injury however, like minocycline, it does not
appear to completely ameliorate damage to this neuronal
network. Thus it is plausible thatother mechanisms of injury6 Neurology Research International
also contribute to HI-induced serotonergic damage in the
neonatal brain.
7. Lackof P3 HI-InducedNeuroinﬂammatory
Mediatorsinthe Brainstem
From our studies, it is interesting to note that a pattern of
neuroinﬂammation is beginning to emerge. The brainstem
dorsal raph´ e and frontal cortex, for example, represent
two areas where neuroinﬂammatory mediator proﬁles diﬀer
markedly. In the frontal cortex substantial and signiﬁ-
cant increases in activated microglia and proinﬂammatory
cytokines occur after P3 HI. In contrast, in the brainstem,
we have observed that the brainstem does not elicit any
major signs of neuroinﬂammation after P3 HI. Numbers of
activated microglia are relatively small, there are no apparent
changes in proinﬂammatory cytokines [67] and more recent
data from our laboratory indicates there are no changes
in COX-2 expression in raph´ e serotonergic subdivisions
(unpublished). It therefore appears that serotonergic raph´ e
cellbodiesarenotlostbecauseoflocalneuroinﬂammationin
thebrainstem.Thus,eventhoughinhibition ofneuroinﬂam-
mation has a signiﬁcant beneﬁcial eﬀect on P3 HI-induced
losses of raph´ en e u r o n s[ 67], we speculate that the eﬀects of
anti-inﬂammatorydrugssuchasminocyclinearenotdirectly
eﬀective at the level of the raph´ e nuclei. We postulate that the
losses of 5-HT-positive neurons in the brainstem after P3 HI,
and the neuroprotective eﬀects of minocycline are therefore
likely to occur via other, indirect secondary mechanisms.
As stated earlier, at least in our model, the brainstem
is located outside the vascular ﬁeld of the common carotid
artery and should not be directly aﬀected by immediate
changes in perfusion after HI. Instead neuroinﬂammation
could contribute to brainstem injury via remote actions
originating from primary injury sites. Inﬂammatory medi-
ators may damage aﬀerent and eﬀerent ﬁbres of dorsal
raph´ e nuclei in the forebrain and subsequently compromise
the survival of brainstem nuclei by retrograde degenera-
tion and/or target deprivation. The thalamus, substantia
nigra, hippocampus, and amygdala have substantial neural
connections with primary injury sites (e.g., the cerebral
cortex) and can undergo prolonged periods of apoptosis and
degeneration in the neonatal brain after HI [25–27, 146].
It has been shown that after ischemic conditions, disrupted
somatosensory transmission in the thalamus is associated
with increased numbers of thalamic neurons degenerating
in the secondary phase [26, 147, 148]. Progressive loss of
serotonergic neural connections with damaged areas could
lead to the disruption and loss of raph´ e serotonergic neurons
in the brainstem. Indeed the regional diﬀerences in vulner-
ability of 5-HT-positive neurons in the dorsal raph´ e nuclei
after P3 HI [58] might be attributed to the serotonergic
innervation pattern to damaged and undamaged forebrain
regions.
The two mechanisms of HI-induced neuroinﬂammation
and neural disruption may not be mutually exclusive.
Activated microglia have also been shown to be present in
brain regions as a consequence of a loss of connectivity with
a target region or axonal interruption [149–151]. It remains
to be investigated whether forebrain neuroinﬂammation
after neonatal HI initiates subsequent serotonergic neuronal
damage in the remote brainstem via retrograde degeneration
and/or target deprivation mechanisms.
8. Conclusions andFutureDirections
We have identiﬁed the serotonergic system as a pervasive
network that is disrupted after neonatal HI in a rodent
model. The concomitant reductions in SERT, 5-HT levels
and 5-HT-positive raph´ e neurons suggest that serotonergic
networkinjuryisaconsequenceofdegeneratingserotonergic
neurons that project to the HI-damaged forebrain. A change
in the levels of 5-HT in the brain gives a “readout” of
the functional integrity of the serotonergic system. However
determining how the synthesis of 5-HT is aﬀected, the
storage, release mechanisms, postsynaptic signaling and the
breakdown of 5-HT would further our understanding of
how HI-injury aﬀects the serotonergic network and possibly
reveal new targets for selective interventions. Moreover
key components of the serotonergic system have been a
critical focus of our recent work, but whether serotonergic
changes manifest as speciﬁc impairments of neurological
performance is not known. It is plausible that disruption
of the serotonergic system may underpin impairments such
as hyperactivity, cardiorespiratory, cognitive, and attention
deﬁcits observed in preterm children who have experienced
neonatal HI [4–7, 152]. Also, current theories implicate a
disrupted 5-HT neurocircuitry in the brainstem raph´ en u c l e i
as the putative underlying mechanism of cardiorespiratory
dysfunction in neonates and increased susceptibility to SIDS
[41, 153–155]. Being born preterm is a signiﬁcant risk factor
for SIDS [156] and exposure to a HI insult may be suﬃcient
to alter raph´ e serotonergic function and increase a neonate’s
susceptibility to later cardiorespiratory complications and
possibly SIDS [41, 155].
The serotonergic system does show some degree of
recovery weeks after the initial P3 HI insult [58, 68]. Greater
density of serotonergic innervation, increased arborization
and axonal length, and higher expression of the SERT occur
in the postnatal brain; indicating plasticity and temporal
diﬀerences depending on the region examined [157–159]. It
is also remarkable that serotonergic neurons have an ability
to sprout and potentially reinnervate after injury [160–162].
In the HI-injured neonatal brain this avenue of investigation
remains to be explored, and possibly exploited, to test new
therapeutic strategies.
To date, evidence suggests that both minocycline and
ibuprofen are successful postinsult interventions to amelio-
rate neuroinﬂammation and reducing neuronal loss. Both
of these potential anti-inﬂammatory treatments could be
beneﬁcial for HI-induced injury to other neurons in the
brain [163–165]. However neither intervention appears to
be suﬃcient to completely reverse the HI-induced decrease
in brain 5-HT levels. The dose, timing, and speciﬁcity
of anti-inﬂammatory interventions are likely to be key
parametersthatdictatetheirsuccess.Alternatively,selectively
targeting the serotonergic system to improve its function,
in concert with changes produced by anti-inﬂammatoryNeurology Research International 7
drugs, could be an ideal combination treatment to achieve
long-term improvement of the serotonergic system after
neonatalHI.Byunderstandingthefundamentalmechanisms
of serotonergic damage after neonatal HI we will hopefully
move closer to providing a clinical intervention.
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